Propranolol Hydrochloride Psychiatric Effectiveness and Oxidative Stress: An Update
Raphaël Serreau,
Ammar Amirouche,
Amine Benyamina,
Sabine Berteina-Raboin
Affiliations
Raphaël Serreau
Unité de Recherche Psychiatrie-Comorbidités-Addictions (PSYCOMadd), APHP Université Paris Saclay, Hôpital Paul-Brousse, 12 Avenue Paul Vaillant Couturier, 94804 Villejuif, France
Ammar Amirouche
Unité de Recherche Psychiatrie-Comorbidités-Addictions (PSYCOMadd), APHP Université Paris Saclay, Hôpital Paul-Brousse, 12 Avenue Paul Vaillant Couturier, 94804 Villejuif, France
Amine Benyamina
Unité de Recherche Psychiatrie-Comorbidités-Addictions (PSYCOMadd), APHP Université Paris Saclay, Hôpital Paul-Brousse, 12 Avenue Paul Vaillant Couturier, 94804 Villejuif, France
Sabine Berteina-Raboin
Institut de Chimie Organique et Analytique (ICOA), Université d’Orléans, UMR-CNRS 7311, BP 6759, Rue de Chartres, 45067 Orléans, France
In this review, in addition to the potential cardiovascular applications of β-blockers and, more specifically, propranolol, we wanted to list the more recent applications in psychiatry as well as current knowledge on the impact of oxidative stress on propranolol hydrochloride and the oxidative stress that could be limited by the latter. In fact, a number of studies show that this molecule is modified by oxidative stress but is also able to limit it. Mention is also made to studies on the increasingly important problem of eliminating drug waste and its impact on the environment, particularly the marine environment. Given the increase in the consumption of medicines, more rigorous waste management is needed to avoid impacting biodiversity.